



Fort Dodge Animal Health

Division of Wyeth
Huizerstraatweg 117
1411 GM NAARDEN
The Netherlands

31 March 2009

First Combination Vaccine for Bluetongue Serotypes 1 and 8 in Europe Developed by Fort Dodge

Global vaccine specialist Fort Dodge has become the first manufacturer to develop a combination vaccine to protect sheep and cattle against both Bluetongue Serotypes 1 and 8.

The development of the new vaccine was triggered by recent outbreaks of both Serotypes of the disease in the same area of France and Spain. The company says that the Bluetongue Serotypes 1 and 8 restriction zones are overlapping more and more as Serotype 1 moves rapidly further north and Serotype 8 moves south,

Fort Dodge has obtained a provisional licence for the use of combination vaccines Zulvac®1+8 Bovis and Zulvac® 1+8 Ovis vaccine in Spain. The first deliveries are underway with further supply of the vaccines expected over the next few months. The combination vaccines are produced at its manufacturing plant in Olot, Spain.

Marc Snacken, Business Manager Livestock, Fort Dodge Europe, Africa and Middle East, commented: “The new situation where Bluetongue Serotypes are mixing has created a difficult situation for farmers as mono-valent vaccines provide no cross-protection against other Serotypes.

“As a leader in the single Serotype vaccine market, we were well placed to start work immediately on a combination vaccine and we are delighted that the dossiers for both the sheep and cattle versions have now been submitted in Spain.



“The new combination vaccine will offer vets and farmers a further tool in the fight against this dreadful disease and will enable them to plan their vaccination campaigns more effectively.”

Fort Dodge Animal Health is a division of the Wyeth (NYSE: WYE), one of the largest research-based pharmaceutical and healthcare products companies in the world. Fort Dodge is a leading manufacturer and marketer of animal health products for the companion animal, equine, livestock, swine and poultry industries in North America and international markets. Key products include ProMeris[®], ProMeris Duo[®], Duramune[®] Fevaxyn[®], Duvaxyn[®], Suvaxyn[®], Poulvac[®], Cydectin[®], and Equest[®] and Equest Pramox[®].

The statements in this press release that are not historical facts are forward-looking statements based on current expectations of future events and are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.

These risks and uncertainties include risks associated with the inherent uncertainty of the timing and success of product research, development and commercialisation (including with respect to our pipeline products), drug pricing and payment for our products by government and third-party payors, manufacturing, data generated on the safety and efficacy of our products, economic conditions including interest and currency exchange rate fluctuations, changes in generally accepted accounting principles, the impact of competitive or generic products, trade buying patterns, global business operations, product liability and other types of litigation, the impact of legislation and regulatory compliance, intellectual property rights, strategic relationships with third parties, environmental liabilities, and other risks and uncertainties, including those detailed from time to time in our periodic reports filed with the Securities and Exchange Commission, including our current reports on Form 8-K, quarterly reports on Form 10-Q and annual report on Form 10-K, particularly the discussion under the caption “Item 1A, RISK FACTORS.” We assume no obligation to publicly update any forward-looking statements, whether as a result of new information, future developments or otherwise.

For further information:

Rebecca George
George PR
Tel: 01449 737281/07974 161108